OpGen, Inc. (OPGN)
Market Cap | 4.54M |
Revenue (ttm) | 3.31M |
Net Income (ttm) | -40.73M |
Shares Out | 3.22M |
EPS (ttm) | -18.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 795,866 |
Open | 1.50 |
Previous Close | 1.55 |
Day's Range | 1.31 - 1.54 |
52-Week Range | 0.93 - 17.56 |
Beta | -0.22 |
Analysts | Sell |
Price Target | 32.23 (+2,185.82%) |
Earnings Date | Apr 4, 2023 |
About OPGN
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also com... [Read more]
Financial Performance
In 2021, OpGen's revenue was $4.31 million, an increase of 2.17% compared to the previous year's $4.21 million. Losses were -$41.97 million, 60.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for OPGN stock is "Sell." The 12-month stock price forecast is $32.23, which is an increase of 2,185.82% from the latest price.
News

OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infect...

OpGen Announces Exercise of All Prefunded Warrants
ROCKVILLE, Md., Feb. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen subsidiary Ares Genetics announces granting of key patent in China
ROCKVILLE, Md., Jan. 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
ROCKVILLE, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
Successful delivery of milestones triggers milestone payment Successful delivery of milestones triggers milestone payment

OpGen Announces Closing of $7.5 Million Public Offering
ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Announces Pricing of $7.5 Million Public Offering
ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Announced 1-for-20 Reverse Stock Split
ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

Why Is OpGen (OPGN) Stock Up 148% Today?
OpGen (NASDAQ: OPGN) stock is rocketing higher on Tuesday after posting results from its Unyvero urinary tract infections ( UTI) clinical trial. This clinical trial covered Unyvero UTI Panel's abili...

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 202...

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infe...

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostic...

OpGen Announces Closing of $3.38 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen Announces $3.38 Million Registered Direct Offering
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform
ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
This in-person and virtual (hybrid) conference to be held September 12-14, 2022 This in-person and virtual (hybrid) conference to be held September 12-14, 2022

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory
ROCKVILLE, Md., Aug. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to he...

OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update
ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 20...

OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
ROCKVILLE, Md., July 26, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”) announced today that its subsidiary Ares Genetics GmbH (Ares Genetics), which strives to become a leader in bacter...

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update
ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infe...